stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Current ratio
Haemonetics Corporation's current ratio at the end of the quarter to 30 September 2026 was 2.8×, down 0.1× from fiscal 2026 (3.0×). Over the past ten years it has ranged from 1.4× (fiscal 2018) to 3.1× (fiscal 2023); the current reading is higher than 83% of that period. That is in line with the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2026 | 3.0× | 82.67% |
| FY2025 | 1.6× | (36.82%) |
| FY2024 | 2.6× | (16.26%) |
| FY2023 | 3.1× | 78.82% |
| FY2022 | 1.7× | (37.52%) |
| FY2021 | 2.7× | 24.56% |
| FY2020 | 2.2× | (10.12%) |
| FY2019 | 2.4× | 80.37% |
| FY2018 | 1.4× | (43.91%) |
| FY2017 | 2.4× | (8.18%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 2.8× | (7.68%) |
| Jun 2026 | 3.1× | 4.26% |
| Mar 2026 | 3.0× | 69.01% |
| Dec 2025 | 1.7× | 6.53% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| AXGN AxoGen, Inc. compare | 12.0× |
| TXG 10x Genomics compare | 5.7× |
| ITGR Integer Holdings Corporation compare | 4.0× |
| IRTC iRhythm Holdings, Inc. compare | 3.6× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.2× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.2× |
| HAE Haemonetics Corporation | 2.8× |
| BRKR Bruker Corporation compare | 1.8× |
| LIVN LivaNova PLC compare | 1.7× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement